Survival analysis showed that CRC patients (GSE17538) with higher SRSF9 expression exhibited significantly poorer overall survival (OS) (P = 0.0052) and had higher risk of death (HR = 3.3) (Fig. 1H), indicating that CRC patients with elevated expression of SRSF9 generally had poor prognoses. Here, SRSF9 is linked to colorectal carcinoma.